BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23912840)

  • 1. Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.
    Okada M; Shibuya K; Sato A; Seino S; Watanabe E; Suzuki S; Seino M; Kitanaka C
    Oncol Rep; 2013 Oct; 30(4):1957-64. PubMed ID: 23912840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.
    Liu Y; Zhang X; Wang J; Yang J; Tan WF
    Acta Pharmacol Sin; 2015 Sep; 36(9):1099-106. PubMed ID: 26235742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.
    Okada M; Shibuya K; Sato A; Seino S; Suzuki S; Seino M; Kitanaka C
    Oncotarget; 2014 Jul; 5(13):5100-12. PubMed ID: 24947996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of phosphorylated JNK in esophageal squamous cell carcinomas of Kazakh ethnic.
    Qin X; Zheng S; Liu T; Liu Q; Liang M; Li X; Sheyhidin I; Lu X
    Mol Carcinog; 2014 Jul; 53(7):526-36. PubMed ID: 23359384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells.
    Cui J; Wang Q; Wang J; Lv M; Zhu N; Li Y; Feng J; Shen B; Zhang J
    Mol Cancer Ther; 2009 Dec; 8(12):3214-22. PubMed ID: 19996270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest.
    Kuntzen C; Sonuc N; De Toni EN; Opelz C; Mucha SR; Gerbes AL; Eichhorst ST
    Cancer Res; 2005 Aug; 65(15):6780-8. PubMed ID: 16061660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
    Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
    J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis.
    Alexaki VI; Javelaud D; Mauviel A
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):429-38. PubMed ID: 18541008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
    Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
    Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
    Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
    Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies.
    Xue X; Sun DF; Sun CC; Liu HP; Yue B; Zhao CR; Lou HX; Qu XJ
    Lung Cancer; 2012 Jun; 76(3):300-8. PubMed ID: 22261315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin.
    Suwei D; Liang Z; Zhimin L; Ruilei L; Yingying Z; Zhen L; Chunlei G; Zhangchao L; Yuanbo X; Jinyan Y; Gaofeng L; Xin S
    J Hematol Oncol; 2015 Oct; 8():120. PubMed ID: 26503334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells.
    Seino M; Okada M; Shibuya K; Seino S; Suzuki S; Ohta T; Kurachi H; Kitanaka C
    Anticancer Res; 2014 Sep; 34(9):4723-31. PubMed ID: 25202050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.
    Song W; Ma Y; Wang J; Brantley-Sieders D; Chen J
    Cancer Res; 2014 May; 74(9):2444-54. PubMed ID: 24607842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting MUC1 and JNK by RNA interference and inhibitor inhibit the development of hepatocellular carcinoma.
    Wang J; Ni WH; Hu KB; Zhai XY; Xie F; Jie J; Zhang NN; Jiang LN; Yuan HY; Tai GX
    Cancer Sci; 2017 Mar; 108(3):504-511. PubMed ID: 28012230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
    Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
    Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phanginin R Induces Cytoprotective Autophagy via JNK/c-Jun Signaling Pathway in Non-Small Cell Lung Cancer A549 Cells.
    Zhang LL; Bao H; Xu YL; Jiang XM; Li W; Zou L; Lin LG; Lu JJ
    Anticancer Agents Med Chem; 2020; 20(8):982-988. PubMed ID: 32286950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.
    Parra E; Ferreira J
    Oncol Rep; 2013 Oct; 30(4):1936-42. PubMed ID: 23900581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.